Aligos (ALGS) news
Recent news
Aligos Therapeutics - eligible for up to $420 mln in milestones and tiered royalties
Aligos Therapeutics (NASDAQ: ALGS) has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium in Greater China for the treatment of chronic hepatitis B virus (HBV) infection. Under the terms of the agreement, Aligos will…
AInvest Wire · Jul 6, 2026Aligos Therapeutics receives upfront payment of $25M USD from the exclusive license deal of Pevifoscorvir Sodium in Greater China for chronic hepatitis B virus infection
Aligos Therapeutics (NASDAQ: ALGS) has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium in Greater China for the treatment of chronic hepatitis B virus (HBV) infection. Under the terms of the agreement, Aligos will…
AInvest Wire · Jul 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.